Scholarlink

<p>Endometriosis diagnosis is often limited by the resolution of conventional imaging techniques (ultrasound/non-targeted MRI) as well as the invasiveness and recurrence risks associated with laparoscopy. To overcome these challenges, we developed anti-MMP-9 peptide-conjugated NaGdF<sub>4</sub>@PEG-Cy5.5 nanoparticles (NPPCNs), which integrate NaGdF<sub>4</sub> cores to enhance T1 relaxivity and biocompatibility for MMP-9-targeted molecular imaging.&#xa0;In vitro&#xa0;studies confirmed both cytocompatibility and high-affinity MMP-9 binding.&#xa0;In vivo&#xa0;biodistribution, assessed through T1-weighted MRI and fluorescence imaging within 48&#xa0;h post-injection, revealed significant nanoparticle accumulation in endometriotic lesions, with elevated signal intensity compared to controls. This MMP-9-targeted theranostic platform offers a non-invasive method for lesion detection, providing a novel approach for precise diagnosis and surgical navigation in endometriosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineering Anti-MMP-9 Peptide-Modified Nanoparticles for Precision MRI Diagnosis of Endometriosis

  • 期刊论文

  • 发表日期：

    2026年2月27日

查看全文
  • Qi Zhang,
  • Haicheng Li,
  • Linghui Xu,
  • Shiman Wu,
  • Yujia Shen,
  • Yiting Wang,
  • Xiongrui Guo,
  • Qianwen Zhu,
  • Xiaohong Ruan,
  • Junhai Zhang

摘要

Endometriosis diagnosis is often limited by the resolution of conventional imaging techniques (ultrasound/non-targeted MRI) as well as the invasiveness and recurrence risks associated with laparoscopy. To overcome these challenges, we developed anti-MMP-9 peptide-conjugated NaGdF4@PEG-Cy5.5 nanoparticles (NPPCNs), which integrate NaGdF4 cores to enhance T1 relaxivity and biocompatibility for MMP-9-targeted molecular imaging. In vitro studies confirmed both cytocompatibility and high-affinity MMP-9 binding. In vivo biodistribution, assessed through T1-weighted MRI and fluorescence imaging within 48 h post-injection, revealed significant nanoparticle accumulation in endometriotic lesions, with elevated signal intensity compared to controls. This MMP-9-targeted theranostic platform offers a non-invasive method for lesion detection, providing a novel approach for precise diagnosis and surgical navigation in endometriosis.